FIELD: biotechnology.
SUBSTANCE: disclosed is an antibody specific to BTN2A1. Also disclosed is the use of said antibody for enhancing macrophage-mediated immunity in a patient suffering cancer or an infectious disease. Invention also relates to a nucleic acid coding said antibody and a host cell containing such a nucleic acid.
EFFECT: invention can find application in therapy for treating cancer and infectious diseases.
21 cl, 56 dwg, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| RECOMBINANT YEAST CELLS PRODUCING POLYLACTIC ACID AND THEIR USE | 2016 |
|
RU2758138C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
